INTRODUCTION
Coenzyme Q10 (CoQ), also known as ubiquinone, is crucial for the function of mitochondrial respiratory chain complexes. Currently, the pathway of CoQ biosynthesis is known to involve at least 18 proteins. Primary CoQ deficiencies in humans involve genetic mutations in COQ2, PDSS1, PDSS2, COQ8A, COQ9, COQ6, COQ4, or COQ7. 1 The primary CoQ10 deficiency-7 (COQ10D7, MIM: 616276) is caused by autosomal-recessive mutations in COQ4. COQ4 is hypothesized to take part in stabilizing the CoQ complex. 2 To date, biallelic COQ4 mutations have been described in 16 patients from 11 unrelated families. They were reported in two case series (with five to six cases each) and three case reports. The patients described had common features of cardiomyopathy, encephalopathy, lactic acidosis often with a neonatal onset, and death in the neonatal or infantile period. [2] [3] [4] Two siblings of childhood onset presenting with spinocerebellar ataxia and stroke-like episodes 5 and two Chinese siblings with neonatal onset of dystonia, seizures, lactic acidosis, and cerebellar atrophy were described in recent case reports. 6 In this report, we have 11 patients (4 males and 7 females) from 9 unrelated families who were managed by the Medical Genetics division of the Department of Paediatrics and Adolescent Medicine at the University of Hong Kong and the Department of Medical Genetics and Pediatrics at the National Taiwan University Hospital in the period of 2014-2018. They presented with two overlapping phenotypes: the classical neonatal-onset encephalocardiomyopathy and infantile-onset encephalopathy with or without cardiomyopathy. They were diagnosed as COQ10D7 due to homozygous or compound heterozygous COQ4 mutations. All genetic diagnoses were made by whole-exome sequencing (WES) except Patient 4, Patient 5, and Patient 11 due to their known family history and recognizable features of COQ10D7. More importantly, we have identified a Chinese-specific COQ4 founder mutation in 10 subjects, 5 of whom are homozygous for that mutation.
CASE REPORTS
The study was approved by the institutional review board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (UW12-211) and the National Taiwan University Hospital (201703073RINB). Written informed consent was obtained from subjects or their parents. A summary of the clinical, biochemical, and radiological characteristics of the 11 patients with COQ4 mutations identified is presented in Table 1 . Patients 1-5 had the classical neonatal-onset phenotype described by Brea-Calvo et al. and Chung et al., 2, 3 whereas Patients 6-11 had later onset and more heterogeneous features. The frequency of distinct phenotypes compared with previous studies is summarized in Table 2 . The corresponding MRI (magnetic resonance imaging) images are presented in Fig. 1 Sondheimer et al. 4 Bosch et al. 5 Lu et al. 6 Subject Family 1 MRI of the brain at 3 weeks of age showed symmetrical T1 and T2 hyperintensity with restricted diffusion at bilateral lentiform nuclei. Foci of restricted diffusion were also detected at bilateral frontal white matter ( Fig. 1a-c) . Magnetic resonance spectroscopy (MRS) showed raised lactate peaks at bilateral basal ganglia and cerebral white matter. Subsequent follow-up MRI showed established infarcts with cystic changes at bilateral lentiform nuclei ( Fig. 1d ). Mild cerebellar hypoplasia was also noted. Serial echocardiography in the following months showed progressive septal and ventricular myocardial hypertrophy. WES identified compound heterozygous mutations in COQ4, a missense c.370G>A, p. (Gly124Ser) she developed respiratory distress with intermittent apnea and lactic acidemia (up to 10 mmol/L; reference range 0.5-2.2). MRI brain showed symmetrical T1 hyperintensity at bilateral basal ganglia, with mild cerebellar hypoplasia ( Fig. 1e ). MRS showed raised lactate peaks at bilateral basal ganglia ( Fig. 1f ). She developed treatment-resistant seizures at 2 months of age. Subsequent MRI at 9 months of age showed generalized progressive cerebellar and cerebral atrophy, with diffuse white matter loss including thinning of the corpus callosum. Cystic changes were seen within the cerebral white matter, bilateral basal ganglia, and thalami (Fig. 1g ). Serial echocardiogram showed progressive moderate left ventricular hypertrophy. Owing to the recognizable clinical presentation, Sanger sequencing was performed and revealed compound heterozygous COQ4 mutation: c.370G>A, p.(Gly124Ser) and c.402+1G>C. CoQ10 supplement has been started since age of 4 years 5 months. Patient 5 was the elder sister of Patient 4. She was born at 39 weeks with an antenatal history of IUGR. She developed seizures from 2 months of age with associated lactic acidosis and respiratory failure requiring home ventilation. Chest radiograph showed cardiomegaly. CoQ10 supplementation was tried at 1 year of age but passed way from respiratory failure 1 month after. After the genetic diagnosis of her younger sister, Sanger sequencing was performed retrospectively and revealed the same compound heterozygous COQ4 mutation as her sister, c.370G>A, p.(Gly124-Ser) and c.402+1G>C.
Table 2. Phenotypic comparison between patients in this study and previously reported cases
This study Chung et al. 3 Brea-Calvo et al. 2 Sondheimer et al. 4 Bosch et al. 5 Lu et al. 6 Number of subjects  11  6  5  1  2  2 Female-to-male ratio 7:4 6:0 3:2 0:1 1: She also developed an episode of acute myocarditis during which her echocardiogram showed diastolic dysfunction. Brain MRI at 14 months showed mild cerebellar atrophy and cerebral atrophy, white matter cystic changes with bilateral frontal and anterior temporal predominance, and thinning of the corpus callosum. Basal ganglia and brainstem appeared preserved ( Fig. 1h-k) . No lactic acidosis was detected. Owing to the exome findings of her sister, Sanger sequencing was performed and revealed a homozygous COQ4 mutation: c.370G>A, p.(Gly124Ser). She was not on CoQ10 supplement and passed away at 20 months due to an episode of sepsis.
RESULTS

Pathogenicity of the COQ4 variants
We analyzed the COQ4 variants identified in our cohort by previously reported literatures, ClinVar, population frequency in gnomAD, 7 conversation score by Combined Annotation-Dependent Depletion, 8 in silico prediction by Rare Exome Variant Ensemble Learner, 9 and protein stability change prediction by STRUM 10 (Table 3 ). All variants demonstrated a deleterious effect. Together with the reduced level of CoQ10 of the patients, the pathogenicity of these variants is strongly supported by the biochemical findings of the patients.
Founder mutation analysis Among these 11 patients, we identified the same missense mutation c.370G>A, p.(Gly124Ser) in 10 of them. This missense mutation is a rare variant with a population frequency of 0.001118 and it is exclusively found in South East Asians in the gnomAD database. 7 Further analysis of the DNA of the five homozygous patients using Infinium OmniZhongHua-8 BeadChip SNP array showed a common haplotype of 0.464-3.290 cM implying that the mutation was inherited from a common ancestor 27 generations ago (Fig. 3 ). In addition, by principal component analysis), our SNP array data are clustered with Chinese and Japanese of HapMap Phase II (n = 270) and a local southern Chinese database (n = 612). Furthermore, the pathogenicity of this mutation has been established via the reduced CoQ level in the skin fibroblasts in Patients 7 and 9 who have homozygous c.370G>A mutation (Table  4 ). Altogether our study confirms that the missense mutation c.370G>A, p.(Gly124Ser) represents a pathogenic founder mutation in the southern Chinese population.
DISCUSSION
To our knowledge, this is the largest case series of primary COQ10D7 reported. In the literature, primary COQ10D7 cases have been described predominantly with a neonatal onset, with only two cases of childhood onset. [2] [3] [4] [5] 8 In this study, we have expanded the phenotypic spectrum of primary COQ10D7 from neonatal to infantile onset.
We have five patients exhibiting the well-described neonatal presentation of COQ10D7 as in the literature, characterized by respiratory distress, encephalopathy, seizures, hypotonia, and cardiomyopathy. Previously, it was believed that phenotypes from affected males with COQ4 mutation would be more severe and highly likely lethal. 3, 6 However, in our study the male-to-female death ratio was 2:3.
We have six patients with infantile-onset phenotypes. Unlike those of neonatal onset, MRI brain for those infantile-onset patients did not show characteristic basal ganglia lesions. Dystonia was observed in two out of the six patients with infantile-onset presentation in our cohort, and it was also observed in the two neonatal-onset cases reported by Lu et al. 8 but not reported in non-Chinese patient.
A summary of the predominant phenotypes in the spectrum of neonatal, infantile, and childhood onset of COQ10D7 is shown in Fig. 4 . The variegated symptoms and disease onsets explain the frequent delay of diagnoses of COQ10D7. This also highlights the importance of the complementarity of biochemical screening for children with unexplained neurological disturbances and the prompt application of WES in order to reach a genetic diagnosis that has an impact on patient management. Functional analysis to demonstrate the deficiency of CoQ should be carefully examined because mitochondrial enzymology can be tissue specific. In this study, among the five patients ( Patients 1, 6, 7, 8, 9) with ETC chain analysis in the skin fibroblast, all of them shown a reduced level of succinate:cytochrome c oxidoreductase (complex II+III). Measurement of CoQ level was also found significantly decreased. For Patients 7 and 8, complex II +III analysis and CoQ level measurement were also performed in the muscle. Interestingly, the CoQ level from the muscle is normal but that from skin fibroblasts was reduced. From the Genotype-Tissue Expression (GTex) data, the COQ4 median expression in the muscle is 7.58 transcripts per million (TPM) while in the skin it is 44.14 TPM, demonstrating a 6-fold lower expression in the muscle. More significantly, we have identified a common founder pathogenic COQ4 mutation associated with COD10D7. In this study, 10 out of the 11 patients carry the COQ4: c.370G>A, p. (Gly124Ser) allele. This mutation fulfills the criteria of a founder mutation: (1) all patients with the mutant alleles share a haplotype associated with the mutation; (2) the haplotype is shared among affected families with a genetic distance >1 cM; (3) the mutant allele is rare and specific to the population; and (4) all carriers are delineated to the same geographic region. It is likely that this founder mutation causes a relatively higher rate of COQ10D7 in southern Chinese individuals, and that may explain why we can present a larger cohort as compared to past studies in this field.
CoQ10 oral supplementation was previously reported effective in COQ4 mutation cases. [2] [3] [4] 6 Among the 10 patients who received CoQ10 supplement and with continuous follow-up, those shown with stabilized cardiac condition or seizure control are those of genotype of homozygous missense variant c.370G>A (Patients 3, 9, 10). Another patient on CoQ supplement with improved clinical condition is Patient 8 with genotype of compound heterozygous missense variants c.370G>A/c.371G>T. For those without improvement are patients with genotype in the presence of a splicing mutation c.402+1G>A (Patients 1, 2, 4, 5, 6). Among these five patients, three of them (Patients 1, 2, and 5) died from the disease. Retrospectively, Patients 1, 4, and 5 were documented IUGR antenatally. This may suggest that the presence of c.402+1G>A, a loss-of-function mutation, would cause more severe neonatal onset of phenotypes and less responsive to CoQ10 supplement.
In this study, we have expanded the phenotypic spectrum of COQ4 mutation. Now COQ10D7 can range from neonatal, infantile to childhood onset. We have also identified a pathogenic COQ4 founder mutation in the southern Chinese population. The importance of complementarity of biochemical screening and prompt application of WES on patients with unexplained neurological symptoms is highlighted.
Reporting summary Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. 
